Compare ETON & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | NUS |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.1M | 343.1M |
| IPO Year | 2018 | 1996 |
| Metric | ETON | NUS |
|---|---|---|
| Price | $24.92 | $7.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | 383.3K | ★ 446.2K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.30% |
| EPS Growth | N/A | ★ 207.80 |
| EPS | N/A | ★ 3.18 |
| Revenue | $79,950,000.00 | ★ $3,176,718,000.00 |
| Revenue This Year | $34.30 | N/A |
| Revenue Next Year | $36.43 | $7.14 |
| P/E Ratio | ★ N/A | $2.29 |
| Revenue Growth | ★ 104.94 | 48.98 |
| 52 Week Low | $11.09 | $5.32 |
| 52 Week High | $24.90 | $14.62 |
| Indicator | ETON | NUS |
|---|---|---|
| Relative Strength Index (RSI) | 75.14 | 41.49 |
| Support Level | $16.38 | $7.30 |
| Resistance Level | N/A | $10.90 |
| Average True Range (ATR) | 1.35 | 0.20 |
| MACD | 0.35 | 0.11 |
| Stochastic Oscillator | 95.71 | 90.96 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.